RXRX logo

RXRX

Profile

Full Name

Recursion Pharmaceuticals, Inc.

Ticker Symbol

RXRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 16, 2021

Indexes

Not included

Website

http://www.recursion.com

Employees

800

Key Details

Price

$5.73(-0.35%)

Market cap

$2.30B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$58.49M(+33.30% YoY)

Annual EPS

-$1.69(-6.96% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$5.73
RXRX price is $5.73

30-Day Relative Volume

0.61
RXRX 30-day relative volume is 0.61

Price Performance

Price Most recent change

-0.35%
RXRX price was down -0.35% on Apr 25, 2025

Price YTD change

-15.24%
RXRX price is down -15.24% since January 1st

Price 1-year change

-26.91%
RXRX price is down -26.91% year-on-year

Price 3-year change

-15.24%
RXRX price is down -15.24% over the past 3 years

Price Range

Price All-time high

$42.81
RXRX price is currently -86.62% below its historical high of $42.81

Price 3-year low

$3.79
RXRX price is currently +51.19% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$2.30B
RXRX market capitalization is $2.30 billion

Market cap 3-year change

+98.48%
RXRX market capitalization is up +98.48% over the past 3 years

Market cap All-time high

$6.96B
RXRX market capitalization is currently -66.91% below its historical high of $6.96 billion

Market cap sector rank

84.26%
RXRX market capitalization is higher than 84.26% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+69.24%
RXRX shares outstanding is up +69.24% year-on-year

Shares Outstanding 3-Year Change

+134.16%
RXRX shares outstanding is up +134.16% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

2.38
RXRX beta is 2.38

200-day SMA

$6.87
RXRX price is currently -16.65% below its 200-day simple moving average

50-day SMA

$6.52
RXRX price is currently -12.14% below its 50-day simple moving average

RSI

51.09
RXRX 14-day relative strength index is 51.09

Volume

0.61
RXRX 30-day relative volume is 0.61

ATR

$0.51
RXRX average true range is $0.51

10-day Historical Volatility

148.65%
RXRX 10-day historical volatility is 148.65%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$58.49M
RXRX annual revenue is $58.49 million

Revenue Analysts estimate

$88.31M
RXRX annual revenue is currently -33.77% lower than the consensus analysts' forecast

Revenue 1-year change

+33.3%
RXRX annual revenue is up +33.3% year-on-year

Revenue Sector rank

49.15%
RXRX annual revenue is higher than 49.15% of companies in Healthcare sector

EPS

EPS

-$1.69
RXRX annual earnings per share is -$1.69

EPS Analysts estimate

-$1.61
RXRX annual earnings per share is currently +5.03% higher than the consensus analysts' forecast

EPS 1-year change

-6.96%
RXRX annual earnings per share is down -6.96% year-on-year

EPS Sector rank

41.65%
RXRX annual earnings per share is higher than 41.65% of companies in Healthcare sector

Profit

Gross profit

$13.25M
RXRX annual gross profit is $13.25 million

Gross margin

22.65%
RXRX annual gross profit margin is 22.65%

Operating profit

-$479.00M
RXRX annual operating income is -$479.00 million

Operating margin

-818.98%
RXRX annual operating profit margin is -818.98%

Net income

-$463.66M
RXRX annual net profit is -$463.66 million

Net margin

-792.75%
RXRX annual net profit margin is -792.75%

Expenses

Total expenses

$537.49M
RXRX annual total expenses is $537.49 million

Operating expenses

$492.25M
RXRX annual total operating expenses is $492.25 million

Cost of goods sold

$45.24M
RXRX annual cost of goods sold is $45.24 million

Selling, general & administrative expenses

$178.18M
RXRX annual SGA is $178.18 million

Depreciation and amortization

$36.49M
RXRX annual depreciation & amortization is $36.49 million

Interest expense

$1.57M
RXRX annual interest expense is $1.57 million

Income tax

-$1.13M
RXRX annual income tax is -$1.13 million

EBIT & EBITDA

EBIT

-$463.22M
RXRX annual earnings before interest & taxes is -$463.22 million

EBITDA

-$426.72M
RXRX annual EBITDA is -$426.72 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.45B
RXRX annual total assets is $1.45 billion

Non current assets

$734.33M
RXRX annual long term assets is $734.33 million

Current assets

$714.27M
RXRX annual total current assets is $714.27 million

Cash and cash equivalents

$594.35M
RXRX annual cash & cash equivalents is $594.35 million

Accounts receivable

-
RXRX annual accounts receivable value is unknown

Inventory

-
RXRX annual inventory value is unknown

Liabilities

Total liabilities

$413.82M
RXRX annual total liabilities is $413.82 million

Long term liabilities

$226.34M
RXRX annual total long term liabilities is $226.34 million

Current liabilities

$187.47M
RXRX annual total current liabilities is $187.47 million

Accounts payable

$21.61M
RXRX annual accounts payable is $21.61 million

Debt

Total debt

$108.49M
RXRX annual total debt is $108.49 million

Total debt 1-year change

+114.11%
RXRX annual total debt is up +114.11% year-on-year

Long term debt

$86.27M
RXRX annual long term debt is $86.27 million

Short term debt

$22.22M
RXRX annual short term debt is $22.22 million

Equity & Capital

Shareholders equity

$1.03B
RXRX annual stockholders equity is $1.03 billion

Book value

$1.03B
RXRX annual book value is $1.03 billion

Retained earnings

-$1.43B
RXRX annual retained earnings is -$1.43 billion

Working capital

$526.80M
RXRX annual working capital is $526.80 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$359.17M
RXRX annual cash flow from operations is -$359.17 million

Cash from operations 1-year change

-24.81%
RXRX annual cash flow from operations is down -24.81% year-on-year

Cash from investing

$260.06M
RXRX annual cash flow from investing activities is $260.06 million

Cash from investing 1-year change

+2642.62%
RXRX annual cash flow from investing activities is up +2642.62% year-on-year

Cash from financing

$304.12M
RXRX annual cash flow from financing activities is $304.12 million

Cash from financing 1-year change

+117.02%
RXRX annual cash flow from financing activities is up +117.02% year-on-year

CAPEX

CAPEX

$17.05M
RXRX annual capital expenditures is $17.05 million

CAPEX 1-year change

+35.8%
RXRX annual capital expenditures is up +35.8% year-on-year

Free Cash Flow

Free cash flow

-$376.22M
RXRX annual free cash flow is -$376.22 million

Free cash flow 1-year change

-25.27%
RXRX annual free cash flow is down -25.27% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

22.65%
RXRX annual gross profit margin is 22.65%

Operating margin

-818.98%
RXRX annual operating profit margin is -818.98%

Net margin

-792.75%
RXRX annual net profit margin is -792.75%

ROA & ROE

ROA

-44.11%
RXRX annual return on assets is -44.11%

ROE

-61.90%
RXRX annual return on equity is -61.90%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
RXRX price to earnings ratio value is unknown

PE ratio Sector rank

-
RXRX price to earnings ratio is unknown

PB Ratio

PB ratio

2.23
RXRX price to book ratio is 2.23

PB ratio Sector rank

64.04%
RXRX price to book ratio is higher than 64.04% of companies in Healthcare sector

PS Ratio

PS ratio

39.38
RXRX price to sales ratio is 39.38

PS ratio Sector rank

89.87%
RXRX price to sales ratio is higher than 89.87% of companies in Healthcare sector

Enterprise value

Enterprise value

$1.82B
RXRX enterprise value is $1.82 billion

Enterprise value Sector rank

80.82%
RXRX enterprise value is higher than 80.82% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-4.26
RXRX EV/EBITDA is -4.26

EV/EBITDA Sector rank

21.64%
RXRX EV/EBITDA is higher than 21.64% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

3.81
RXRX annual current ratio is 3.81

Quick ratio

-
RXRX annual quick ratio value is unknown

Leverage

Debt to equity

0.03
RXRX annual debt to equity ratio is 0.03

Interest coverage ratio

-294.67
RXRX annual interest coverage ratio is -294.67

Risk & Stability

Piotroski F-Score

1
RXRX piotroski f-score is 1

Altman Z-Score

1.38
RXRX altman z-score is 1.38

Analyst ratings

Recent major analysts updates

Apr 10, 25 Morgan Stanley
Equal-Weight
Apr 8, 25 Needham
Buy
Feb 28, 25 Leerink Partners
Market Perform
Feb 6, 25 Needham
Buy
Jan 8, 25 Keybanc
Overweight
Dec 11, 24 Needham
Buy
Nov 20, 24 Needham
Buy
Nov 7, 24 Needham
Buy
Sep 4, 24 Needham
Buy
Sep 3, 24 Leerink Partners
Market Perform

Institutional Ownership

Similar stocks

Ascentage Pharma Group International (AAPG)
AMRX logo
Amneal Pharmaceuticals (AMRX)
CERT logo
Certara (CERT)
DNLI logo
Denali Therapeutics (DNLI)
FOLD logo
Amicus Therapeutics (FOLD)
SEM logo
Select Medical Holdings (SEM)
IBRX logo
ImmunityBio (IBRX)
TWST logo
Twist Bioscience (TWST)
ALVO logo
Alvotech (ALVO)
  • What is the ticker symbol for Recursion Pharmaceuticals?
  • Does Recursion Pharmaceuticals pay dividends?
  • What sector is Recursion Pharmaceuticals in?
  • What industry is Recursion Pharmaceuticals in?
  • What country is Recursion Pharmaceuticals based in?
  • When did Recursion Pharmaceuticals go public?
  • Is Recursion Pharmaceuticals in the S&P 500?
  • Is Recursion Pharmaceuticals in the NASDAQ 100?
  • Is Recursion Pharmaceuticals in the Dow Jones?
  • When was Recursion Pharmaceuticals's last earnings report?
  • When does Recursion Pharmaceuticals report earnings?
  • Should I buy Recursion Pharmaceuticals stock now?

What is the ticker symbol for Recursion Pharmaceuticals?

The ticker symbol for Recursion Pharmaceuticals is NASDAQ:RXRX

Does Recursion Pharmaceuticals pay dividends?

No, Recursion Pharmaceuticals does not pay dividends

What sector is Recursion Pharmaceuticals in?

Recursion Pharmaceuticals is in the Healthcare sector

What industry is Recursion Pharmaceuticals in?

Recursion Pharmaceuticals is in the Biotechnology industry

What country is Recursion Pharmaceuticals based in?

Recursion Pharmaceuticals is headquartered in United States

When did Recursion Pharmaceuticals go public?

Recursion Pharmaceuticals's initial public offering (IPO) was on April 16, 2021

Is Recursion Pharmaceuticals in the S&P 500?

No, Recursion Pharmaceuticals is not included in the S&P 500 index

Is Recursion Pharmaceuticals in the NASDAQ 100?

No, Recursion Pharmaceuticals is not included in the NASDAQ 100 index

Is Recursion Pharmaceuticals in the Dow Jones?

No, Recursion Pharmaceuticals is not included in the Dow Jones index

When was Recursion Pharmaceuticals's last earnings report?

Recursion Pharmaceuticals's most recent earnings report was on Feb 28, 2025

When does Recursion Pharmaceuticals report earnings?

The next expected earnings date for Recursion Pharmaceuticals is May 9, 2025

Should I buy Recursion Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page